Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis

被引:70
作者
Fliser, D [1 ]
Kielstein, JT [1 ]
机构
[1] Hannover Med Sch, Dept Internal Med, D-30625 Hannover, Germany
来源
NATURE CLINICAL PRACTICE NEPHROLOGY | 2006年 / 2卷 / 01期
关键词
acute renal failure; continuous renal replacement therapy; intensive care unit; night-time dialysis; sustained low-efficiency dialysis;
D O I
10.1038/ncpneph0060
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Sustained low-efficiency dialysis (SLED) is an increasingly popular extracorporeal renal replacement therapy for patients with renal failure in the intensive care unit (ICU). Several centers across the world employ this 'hybrid' technique, which has advantages of both intermittent and continuous methods. The goal of these centers is to provide an easy-to-perform treatment with reduced solute clearances for prolonged periods. Many centers use standard, sophisticated dialysis equipment for SLED. An increasing number of hospitals in Europe and South America employ a single-pass batch dialysis system, the procedural simplicity of which makes it an ideal modality for SLED in the ICU. All systems offer the advantages of flexible timing of treatment and reduced costs; their ease of handling means that SLED is readily accepted by ICU staff. Prospective controlled studies have shown that SLED clears small solutes with an efficacy comparable to that of intermittent hemodialysis and continuous venovenous hemofiltration (even when the latter employs high rates of fluid substitution). Cardiovascular tolerability associated with SLED is similar to that associated with continuous renal replacement therapy, even in severely ill patients. Nocturnal dialysis - a special form of SLED - has all the advantages outlined above, with the added benefit of unrestricted physician access to the patient during the day, minimizing the interference of renal replacement therapy with other ICU activities.
引用
收藏
页码:32 / 39
页数:8
相关论文
共 51 条
[1]  
Ahern JW., 2004, Hosp Pharm, V39, P138, DOI 10.1177/001857870403900208
[2]  
Alam MG, 2000, AM J KIDNEY DIS, V35, pA9
[3]   A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF [J].
Augustine, JJ ;
Sandy, D ;
Seifert, TH ;
Paganini, EP .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (06) :1000-1007
[4]   Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients [J].
Barenbrock, M ;
Hausberg, M ;
Matzkies, F ;
de la Motte, S ;
Schaefer, RM .
KIDNEY INTERNATIONAL, 2000, 58 (04) :1751-1757
[5]   High-volume haemofiltration in human septic shock [J].
Cole, L ;
Bellomo, R ;
Journois, D ;
Davenport, P ;
Baldwin, I ;
Tipping, P .
INTENSIVE CARE MEDICINE, 2001, 27 (06) :978-986
[6]   Studies on dialysate mixing in the Genius® single-pass batch system for hemodialysis therapy [J].
Dhondt, AW ;
Vanholder, RC ;
De Smet, RV ;
Claus, SA ;
Waterloos, MA ;
Glorieux, GL ;
Delanghe, JR ;
Lameire, NH .
KIDNEY INTERNATIONAL, 2003, 63 (04) :1540-1547
[7]   Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure [J].
Fiaccadori, E ;
Maggiore, U ;
Rotelli, C ;
Giacosa, R ;
Parenti, E ;
Picetti, E ;
Sagripanti, S ;
Manini, P ;
Andreoli, R ;
Cabassi, A .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2437-2442
[8]   Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients [J].
Finkel, KW ;
Foringer, JR .
RENAL FAILURE, 2005, 27 (05) :541-545
[9]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119
[10]  
Fliser Danilo, 2004, Curr Opin Crit Care, V10, P483, DOI 10.1097/01.ccx.0000145101.58940.dc